Back to top
more

Stryker (SYK)

(Real Time Quote from BATS)

$377.91 USD

377.91
133,811

+1.54 (0.41%)

Updated Aug 8, 2025 10:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Stryker (SYK) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research

Stryker (SYK) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Stryker (SYK) Down 4.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Stryker (SYK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Avanos (AVNS) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Avanos (AVNS) gains from segmental contributions in Q4.

Zacks Equity Research

OPKO Health (OPK) Q4 Loss Narrower Than Estimates, Sales Up

by Zacks Equity Research

OPKO (OPK) gains from increase in RAYALDEE prescriptions.

Zacks Equity Research

LHC Group (LHCG) Q4 Earnings Meet Estimates, Revenues Lag

by Zacks Equity Research

LHC Group (LHCG) fourth-quarter results benefit from home health and hospice admissions and higher revenues.

Zacks Equity Research

Patterson Companies (PDCO) Q3 Earnings Top Estimates, Up Y/Y

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal third-quarter results benefit from higher revenues and solid show by Dental as well as Animal Health segments.

Zacks Equity Research

Humana Extends Value-based Care Services in North Carolina

by Zacks Equity Research

Humana (HUM) strengthens ties with Aledade to expand value-based care services for its Medicare Advantage members in North Carolina.

Zacks Equity Research

Teladoc (TDOC) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Teladoc's (TDOC) Q4 results reflect strong revenue growth, partially offset by high expenses.

Zacks Equity Research

Nevro (NVRO) Q4 Loss Narrower Than Expected, Revenues Up Y/Y

by Zacks Equity Research

Nevro (NVRO) sees strong segmental contributions in Q4.

Zacks Equity Research

Orthofix (OFIX) Q4 Earnings Match Estimates, Margins Decline

by Zacks Equity Research

We are upbeat about the year-over-year revenue growth recorded by majority of Orthofix's (OFIX) key operating segments in Q4.

Zacks Equity Research

Inogen's (INGN) Q4 Earnings Miss, Revenues Top Estimates

by Zacks Equity Research

Inogen (INGN) sees segmental softness in the fourth quarter.

Zacks Equity Research

Penumbra (PEN) Q4 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Penumbra (PEN) registers balanced segmental growth across all geographies in Q4.

Zacks Equity Research

Insulet (PODD) Q4 Earnings Lag Estimates, Revenues Beat

by Zacks Equity Research

Insulet's (PODD) fourth-quarter 2019 results reflect strong segmental performances.

Zacks Equity Research

Intersect ENT (XENT) Reports Narrower-Than-Expected Q4 Loss

by Zacks Equity Research

Intersect ENT (XENT) exhibits a dismal performance in the fourth quarter of 2019.

Zacks Equity Research

Merit Medical (MMSI) Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Merit Medical's (MMSI) fourth-quarter results gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.

Zacks Equity Research

Tandem Diabetes (TNDM) Q4 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Tandem Diabetes (TNDM) once again registers strong domestic pump shipment in Q4.

Zacks Equity Research

Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (SYK) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

PRA Health (PRAH) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Solid Clinical Research revenues drove PRA Health's (PRAH) Q4 results.

Zacks Equity Research

Teleflex (TFX) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Teleflex's (TFX) fourth-quarter 2019 results reflect strong segmental performances.

Zacks Equity Research

HMS Holdings (HMSY) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

HMS Holdings' (HMSY) fourth-quarter earnings benefit from higher revenues at Analytical Services unit and strong 2020 outlook.

Zacks Equity Research

The Zacks Analyst Blog Highlights: NVIDIA, Costco Wholesale, Stryker, Advanced Micro Devices and CSX

by Zacks Equity Research

The Zacks Analyst Blog Highlights: NVIDIA, Costco Wholesale, Stryker, Advanced Micro Devices and CSX

Zacks Equity Research

Integra (IART) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Integra's (IART) fourth-quarter 2019 results reflect strong segmental performances.

Zacks Equity Research

Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y

by Zacks Equity Research

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong segmental performance and solid 2020 EPS outlook.

Zacks Equity Research

Integer Holdings (ITGR) Q4 Earnings & Revenues Top Estimates

by Zacks Equity Research

Integer Holdings' (ITGR) fourth-quarter earnings benefit from higher revenues and strong segmental performance.

Zacks Equity Research

Masimo (MASI) Q4 Earnings Beat Estimates, View Impressive

by Zacks Equity Research

Masimo (MASI) sees expansion in gross and operating margin in Q4.